Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

The hormones in Meriofert bind to LH and FSH receptors on ovarian cells, activating intracellular cyclic AMP signaling. This promotes the growth and maturation of ovarian follicles, increases estradiol production, and triggers the ovulatory surge necessary for the release of a mature oocyte.

The dose of Meriofert is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian response, treatment protocol, and clinical goals. Dosing regimens are not standardized and should follow the prescribing physician’s instructions.

Meriofert is intended for use before conception to facilitate ovulation. Its safety in established pregnancy or while breastfeeding has not been established, and it is generally not recommended for use during these periods. Consultation with a healthcare professional is essential.

To order Meriofert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Meriofert combines both LH and FSH activity, whereas some alternatives provide only FSH (e.g., recombinant FSH) or only LH. The dual activity can more closely mimic natural ovarian stimulation, potentially reducing the need for separate LH supplementation in certain protocols.

Meriofert should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use and allow the solution to reach room temperature before administration, following aseptic technique.

Meriofert is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique, typically in the thigh, buttock, or abdominal wall, according to the prescribed dosing schedule.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalization, multiple pregnancy, severe allergic reactions such as anaphylaxis, and rare thromboembolic events. Patients should be monitored closely for early signs of these complications.

Meriofert is contraindicated in patients with known hypersensitivity to human gonadotropins, active hormone‑dependent malignancies, uncontrolled thyroid disease, or severe ovarian cysts. It should also be avoided in women who are already pregnant or breastfeeding.